messag follow call morn see pre-cal thought got
chanc catch bold manag note dmd competit
bold intern manufactur capabl result expedit timelin vs
cdmo import factor success continu see intern manufactur
key strateg benefit intern extern reiter buy rate
increas pt previous
dmd enter clinic util vector transit
earli audent current work bridg studi via
mous model support transit compani reiter current
manufactur suffici support initi clinic develop addit
capac expans underway
also note bold compet trial patient base exclus
bold highlight consist magnitud effect preclin data
vg/kg dose mous model show transcript correct across tissu
area dystrophin express wt near-ful length n-truncat dystrophin
function muscl improv tibiali anterior compani also present data
show dystrophin local vg/kg though show local
vg/kg dose
durabl dr kevin flanigan evalu anim model six month
manag note result appear durabl improv time
compar microdystrophin gene therapi program aim produc full
slightli truncat protein manag note microdystrophin gene therapi
program full protein lack c-termin
domain may impact long-term cardiac outcom
compani believ quickli expand cell line vitro human
cell line studi share toxicolog studi bold yet engag
regulatori agenc believ human antisens sequenc share
serotyp promot snrna backbon enabl quickli expand
advanc program
collabor econom bold paid up-front nationwid children
hospit typic back-end load mileston royalti undisclos
partner audent note partner special exon
exon
compani optim construct differ combin
antisens sequenc promot exon-skip splice donor/acceptor
sequenc promot rna knockdown
model chang ad dmd amen exon mutat
model increas valu assign compani technolog platform
previous also increas po previous
manag note prior guidanc reflect addit dmd
page analyst certif import disclosur
price target per share previous per share base sum-of-the-part peak revenu analysi appli
multipl peak sale us eu/jp assum discount rate sum-of-the-part basi arriv
po previous po po newli ad sotp
po rest valuat come pipelin platform cash
bold suscept risk appli entir biotech industri includ develop regulatori commerci
manufactur financ ip risk specif bold includ
clinic risk risk includ unexpect safety/efficaci issu failur higher dose improv durabl
trial neg news around earlier pipelin develop
regulatori risk clinic trial ultim success possibl bold medicin approv global regulatori
agenc given novelti gene therapi agenc may requir addit long-term data could delay potenti approv
manufactur risk bold sole supplier product manufactur possibl could issu plant
contamin key employe departur could caus problem delay manufactur progress
page analyst certif import disclosur
mm except per share data
factset consensu
interest incom incom net
incom tax
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
